IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
Rhea-AI Summary
IGM Biosciences (Nasdaq: IGMS), a clinical-stage biotech company specializing in engineered IgM antibodies, has announced its participation in the Stifel 2024 Virtual Immunology and Inflammation Summit. CEO Fred Schwarzer and Head of Research & Autoimmunity, Dr. Mary Beth Harler, will engage in a fireside chat on Tuesday, September 17, 2024, at 9:00 a.m. EDT.
The event will be accessible via a live webcast on the company's investor relations website. Interested parties can view the presentation through the 'Events and Presentations' page. For those unable to attend live, a replay will be available on the company's website for 90 days following the presentation, ensuring widespread access to this important industry event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IGMS gained 4.17%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, and Mary Beth Harler, M.D., Head, Research & Autoimmunity, will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit on Tuesday, September 17, 2024, at 9:00 a.m. EDT.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About IGM Biosciences, Inc.
IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 binding sites. IGM also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com.
Contact:
Argot Partners
David Pitts
212-600-1902
igmbio@argotpartners.com
FAQ
When is IGM Biosciences (IGMS) presenting at the Stifel 2024 Virtual Immunology and Inflammation Summit?
Who will be representing IGM Biosciences (IGMS) at the Stifel 2024 summit?
How can investors access the IGM Biosciences (IGMS) presentation at the Stifel 2024 summit?
How long will the replay of IGM Biosciences' (IGMS) Stifel 2024 summit presentation be available?
